RHYTHM PHARMACEUTICALS, INC. (RYTM) Return on equity 2017–2025
RHYTHM PHARMACEUTICALS, INC. (RYTM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-141.3%FY2025 · since FY2017: -23.3% → -141.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -141.3% | +1058.0 pp |
| FY2024 | -1199.3% | -1090.5 pp |
| FY2023 | -108.8% | -40.3 pp |
| FY2022 | -68.5% | -44.0 pp |
| FY2021 | -24.5% | +56.0 pp |
| FY2020 | -80.5% | -30.4 pp |
| FY2019 | -50.1% | -20.0 pp |
| FY2018 | -30.1% | -6.8 pp |
| FY2017 | -23.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RYTM financial trends
RYTM RevenueRYTM Net incomeRYTM Net marginRYTM Gross profitRYTM Gross marginRYTM Operating incomeRYTM Operating marginRYTM Operating cash flowRYTM Free cash flowRYTM Capital expendituresRYTM Stock buybacksRYTM Dividends paidRYTM Total assetsRYTM Total liabilitiesRYTM Shareholders’ equityRYTM overview →